14.50
-0.18 (-1.23%)
| Previous Close | 14.68 |
| Open | 15.01 |
| Volume | 121,374 |
| Avg. Volume (3M) | 288,160 |
| Market Cap | 377,746,752 |
| Price / Earnings (Forward) | 41.32 |
| Price / Sales | 11.51 |
| Price / Book | 19.04 |
| 52 Weeks Range | |
| Earnings Date | 18 Mar 2025 |
| Profit Margin | -9.80% |
| Operating Margin (TTM) | 8.96% |
| Diluted EPS (TTM) | -0.150 |
| Quarterly Revenue Growth (YOY) | 59.30% |
| Total Debt/Equity (MRQ) | 122.79% |
| Current Ratio (MRQ) | 2.06 |
| Operating Cash Flow (TTM) | 2.12 M |
| Levered Free Cash Flow (TTM) | -18.78 M |
| Return on Assets (TTM) | -2.53% |
| Return on Equity (TTM) | -19.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Eton Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 5.57% |
| % Held by Institutions | 48.62% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (HC Wainwright & Co., 127.59%) | Buy |
| Median | 26.00 (79.31%) | |
| Low | 24.00 (B. Riley Securities, 65.52%) | Buy |
| Average | 27.67 (90.83%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 14.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 19 Mar 2025 | 24.00 (65.52%) | Buy | 14.88 |
| Craig-Hallum | 19 Mar 2025 | 26.00 (79.31%) | Buy | 14.88 |
| HC Wainwright & Co. | 19 Mar 2025 | 33.00 (127.59%) | Buy | 14.88 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 |
| 28 Apr 2025 | Announcement | Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) |
| 01 Apr 2025 | Announcement | Eton Pharmaceuticals Out-Licenses International Rights to Increlex® |
| 18 Mar 2025 | Announcement | Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results |
| 14 Mar 2025 | Announcement | Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 |
| 04 Mar 2025 | Announcement | Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 |
| 03 Mar 2025 | Announcement | Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |